Sulfisoxazole

Otitis

Treatment

2 FDA approvals

3 Active Studies for Sulfisoxazole

What is Sulfisoxazole

Sulfisoxazole

The Generic name of this drug

Treatment Summary

Sulfamethoxazole is a short-term antibiotic that can be used to treat bacterial infections caused by both gram-positive and gram-negative bacteria.

image of different drug pills on a surface

Sulfisoxazole Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Sulfisoxazole

0

Approved as Treatment by the FDA

Sulfisoxazole, otherwise called Sulfisoxazole, is approved by the FDA for 2 uses like Acute Otitis Media (AOM) and Otitis .

Acute Otitis Media (AOM)

Used to treat Acute Otitis Media (AOM) in combination with Erythromycin

Otitis

Used to treat Acute Otitis Media (AOM) in combination with Erythromycin

Effectiveness

How Sulfisoxazole Affects Patients

Sulfisoxazole is an antibiotic that can stop bacteria from multiplying. It works by blocking an essential component of bacteria's metabolism. Most sulfonamides, including sulfisoxazole, can be taken orally, though it can be difficult to administer it in other ways because it is a very alkaline and irritating substance. It is able to spread throughout the body, and particularly high levels are found in fluids in the eye, the pleural cavity, the peritoneum, and the synovial cavity. Although it is not used to treat meningitis anymore, sulfisoxazole still reaches high levels in

How Sulfisoxazole works in the body

Sulfisoxazole works by preventing bacteria from making folic acid. It does this by blocking an enzyme that helps the bacteria combine two molecules in order to form folic acid. Without this enzyme, the bacteria can't make folic acid and can't survive.

When to interrupt dosage

The recommended amount of Sulfisoxazole is contingent upon the determined disorder. The quantity of dosage deviates, as per the method of delivery sketched out in the table hereinafter.

Condition

Dosage

Administration

Otitis

600.0 mg/mL, , 500.0 mg

Oral, , Granule, for suspension - Oral, Tablet - Oral, Tablet, Powder, for suspension, Powder, for suspension - Oral

Warnings

Sulfisoxazole Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Sulfisoxazole.

Common Sulfisoxazole Drug Interactions

Drug Name

Risk Level

Description

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Sulfisoxazole.

Amiodarone

Major

The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Amiodarone.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Artemether.

Sulfisoxazole Toxicity & Overdose Risk

The lowest toxic dose of the drug in mice is 6800mg/kg when taken orally.

image of a doctor in a lab doing drug, clinical research

Sulfisoxazole Novel Uses: Which Conditions Have a Clinical Trial Featuring Sulfisoxazole?

One active clinical trial is underway to assess the potential of Sulfisoxazole to ameliorate Acute Otitis Media (AOM).

Condition

Clinical Trials

Trial Phases

Otitis

3 Actively Recruiting

Not Applicable

Patient Q&A Section about sulfisoxazole

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the brand name for sulfisoxazole?

"The active ingredient in sulfisoxazole is also available under the trade names Sulfafurazole and Gantrisin."

Answered by AI

What is sulfisoxazole used for?

"Sulfisoxazole is an antibiotic used to treat or prevent infections caused by bacteria."

Answered by AI

What bacteria does sulfisoxazole treat?

"This medication is used to treat or prevent a variety of bacterial infections. It may also be used for other purposes not listed in this guide."

Answered by AI

What is the mechanism of action of sulfisoxazole?

"Sulfisoxazole is an antibacterial agent$.

Sulfisoxazole works by preventing the enzyme dihydropteroate synthetase from condensing pteridine with para-aminobenzoic acid (PABA). This inhibits bacterial synthesis of dihydrofolic acid."

Answered by AI

Clinical Trials for Sulfisoxazole

Image of Denver Health and Hospital Authority in Denver, United States.

Interventions for Ear Infections

6 - 17
All Sexes
Denver, CO

This study aims to improve care and reduce unnecessary antibiotic prescribing for children with ear infections. The study will compare the effectiveness of a "gold standard" to a hybrid intervention combined with this gold standard, in order to identify steps to increase parent satisfaction for child ear infection care. The "gold standard" approach is a Health System Level Intervention. On its own, it involves clinician education, tools in electronic medical records, and audit and feedback reports for clinician prescribing habits. The hybrid intervention includes the elements of the health systems level intervention in addition to a Shared Decision-Making component, which allows for both an increase in the role parents play in their child's care, as well as clinician education for how to use this method. The goals of this work are to increase parent satisfaction, reduce antibiotics taken for childhood ear infections, align medical care with the current national guidelines, and evaluate differences in the two intervention groups. Both groups will be evaluated for implementation outcomes to improve dissemination and scalability for future use of these models in antibiotic prescribing for children with ear infections. This study will recruit a diverse group of patients and clinicians to complete surveys, parents to participate in focus groups, and clinicians and administrators to be interviewed in order to meet study aims and receive sufficient feedback on the interventions performed. There are two hypotheses for this research: 1. The Hybrid Intervention will have higher parent satisfaction and reduced antibiotic use compared to the Health-System Level Intervention and 2. The Hybrid Intervention will be more challenging to implement than the Health-System Level Intervention, but will be preferred by parents, clinicians, and administrators.

Recruiting
Has No Placebo

Denver Health and Hospital Authority (+2 Sites)

Holly Frost, MD

Image of Denver Health and Hospital Authority in Denver, United States.

Shorter Antibiotic Courses for Ear Infections

2 - 17
All Sexes
Denver, CO

The overarching goal of this study is to evaluate the effectiveness and implementation outcomes of two low-cost interventions of different intensities to increase prescribing of recommended short antibiotic durations for acute otitis media (AOM) for children 2 years of age and older. A multi-center cluster randomized controlled trial using a hybrid type 2 implementation effectiveness design will be used to evaluate interventions. The High-Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields, whereas the Low-Intensity intervention will include clinician education and EHR changes. In total, 46 community-based clinics and/or urgent care centers across two distinct geographic regions in the United States will be randomized to one of the two interventions. The Practical Robust Implementation and Sustainability Model (PRISM) will be used to guide implementation and the Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) framework will be used to evaluate outcomes. A mixed-methods approach will be used in the pre-implementation and evaluation phases and will utilize quantitative analyses, semi-structured interviews, focus groups, surveys, and cost analyses. National stakeholders at the American Academy of Pediatrics and the Centers for Disease Control and Prevention will assist with dissemination of findings and scaling of interventions.

Waitlist Available
Has No Placebo

Denver Health and Hospital Authority

Timothy C Jenkins, MD